- Home
- NRC vs ESPR Comparison
NRC vs ESPR Comparison
Compare NRC & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRC
- ESPR
- Stock Information
- Founded
- NRC 1981
- ESPR 2008
- Country
- NRC United States
- ESPR United States
- Employees
- NRC N/A
- ESPR N/A
- Industry
- NRC Biotechnology: Commercial Physical & Biological Resarch
- ESPR Biotechnology: Pharmaceutical Preparations
- Sector
- NRC Health Care
- ESPR Health Care
- Exchange
- NRC Nasdaq
- ESPR Nasdaq
- Market Cap
- NRC 394.2M
- ESPR 410.2M
- IPO Year
- NRC N/A
- ESPR 2013
- Fundamental
- Price
- NRC $17.82
- ESPR $2.15
- Analyst Decision
- NRC
- ESPR Buy
- Analyst Count
- NRC 0
- ESPR 5
- Target Price
- NRC N/A
- ESPR $5.13
- AVG Volume (30 Days)
- NRC 89.4K
- ESPR 4.4M
- Earning Date
- NRC 02-11-2025
- ESPR 02-25-2025
- Dividend Yield
- NRC 2.67%
- ESPR N/A
- EPS Growth
- NRC N/A
- ESPR N/A
- EPS
- NRC 1.12
- ESPR N/A
- Revenue
- NRC $144,155,000.00
- ESPR $295,451,000.00
- Revenue This Year
- NRC N/A
- ESPR $186.04
- Revenue Next Year
- NRC N/A
- ESPR $11.25
- P/E Ratio
- NRC $15.51
- ESPR N/A
- Revenue Growth
- NRC N/A
- ESPR 187.12
- 52 Week Low
- NRC $16.50
- ESPR $1.58
- 52 Week High
- NRC $42.00
- ESPR $3.94
- Technical
- Relative Strength Index (RSI)
- NRC 51.30
- ESPR 42.65
- Support Level
- NRC $16.79
- ESPR $2.05
- Resistance Level
- NRC $17.47
- ESPR $2.31
- Average True Range (ATR)
- NRC 0.69
- ESPR 0.14
- MACD
- NRC 0.09
- ESPR 0.01
- Stochastic Oscillator
- NRC 67.69
- ESPR 28.57
About NRC National Research Corporation (Delaware)
National Research Corp is a provider of analytics and insights that facilitate measurement and improvement of the patient and employee experience while also increasing patient engagement and customer loyalty for healthcare providers, payers, and other healthcare organizations. Its portfolio of solutions represents a set of capabilities that individually and collectively provide value to clients. It operates in the United States and Canada, of which key revenue is derived from the United States.
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.